Tumor disappeared after one year of taking Crizotinib

The antitumor efficacy of Crizotinib (Crizotinib) was initially demonstrated in two multicenter, single-arm studies. Based on results from the initial Phase I dose-escalation study, these extended series, at a dose of 250 mg orally twice daily, included 94% of patients who had received prior systemic therapy for advanced or metastatic disease and 76% of patients who had received two or more prior lines of therapy.

Results showed a combined target (complete plus partial) remission rate of 55%, with the majority achieved within the first eight weeks of treatment. When analyzing these two studies, the median duration of response was 42 weeks and 48 weeks, respectively. The 1-year and 2-year survival rates of patients treated with crizotinib were 74% and 54%, respectively, and the median follow-up time was 18 months. If the patient's tumor disappears after taking crizotinib for one year, it indicates that the drug has a better therapeutic effect on the patient. Patients are advised to continue taking their medications as recommended by their doctors and undergo regular check-ups. At the same time, maintaining good living habits, such as quitting smoking and drinking, can help improve the treatment effect.

The original drug Crizotinib has been launched in China and is covered by medical insurance, but it is only reimbursed for patients who meet the indications. The price per box may be around RMB 15,000. The price of the original Turkish version of Crizotinib sold overseas may be more than RMB 10,000 per box (the price may fluctuate due to exchange rates), which is expensive. There are also cheaper generic crizotinib drugs available overseas. The ingredients are basically similar to those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Bangladesh pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to exchange rates).